Cargando…

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

BACKGROUND: Clinical variables may correlate with lack of response to treatment (primary resistance) or clinical benefit in patients with clear cell renal cell carcinoma (ccRCC) treated with anti-programmed death 1/ligand one antibodies. METHODS: In this multi-institutional collaboration, clinical c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Labadie, Brian W., Liu, Ping, Bao, Riyue, Crist, Michael, Fernandes, Ricardo, Ferreira, Laura, Graupner, Scott, Poklepovic, Andrew S., Duran, Ignacio, Maleki Vareki, Saman, Balar, Arjun V., Luke, Jason J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878694/ https://www.ncbi.nlm.nih.gov/pubmed/31767020 http://dx.doi.org/10.1186/s12967-019-02144-7

Ejemplares similares

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
por: Vaddepally, Raju, et al.
Publicado: (2022)

Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
por: Batista-Duharte, Alexander, et al.
Publicado: (2023)

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs
por: Balaji, Aanika, et al.
Publicado: (2020)

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
por: Teng, Yi-Shan, et al.
Publicado: (2023)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management
por: Robles-Alonso, Virginia, et al.
Publicado: (2022)

Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
por: Albandar, Heidar J., et al.
Publicado: (2021)

Occurrence of Possible Rheumatologic Immune-Related Adverse Events (rh-irAEs) Associated with Immune Checkpoint Inhibitor (ICI) Therapy
por: Anjohrin, Suzanne, et al.
Publicado: (2021)

Reader Comment Regarding “Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management”
por: Sauder, Maxwell, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
por: Naidoo, Jarushka, et al.
Publicado: (2023)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
por: Daban, A, et al.
Publicado: (2023)

Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
por: Liu, Jing, et al.
Publicado: (2014)

Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis
por: Wang, QuanQiu, et al.
Publicado: (2018)

Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
por: Eschweiler, Simon, et al.
Publicado: (2022)

Development of an eHealth Tool for Capturing and Analyzing the Immune-related Adverse Events (irAEs) in Cancer Treatment
por: Moradian, Saeed, et al.
Publicado: (2023)

High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
por: Maleki Vareki, Saman
Publicado: (2018)

Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers
por: Labadie, Brian W., et al.
Publicado: (2021)

Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis
por: Ai, Qi, et al.
Publicado: (2022)

The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
por: Ke, Wanhai, et al.
Publicado: (2020)

Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis
por: Zhang, Dongyu, et al.
Publicado: (2021)

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
por: Tarhini, Ahmad A, et al.
Publicado: (2021)

Construction of a prognostic model for HCC based on ferroptosis-related lncRNAs expression and its potential to predict the response and irAEs of immunotherapy
por: Dong, Liangbo, et al.
Publicado: (2023)

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy
por: Bai, Xue, et al.
Publicado: (2021)

Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab
por: Zhou, Huanyu, et al.
Publicado: (2022)

The role of gut microbiome in immune modulation in metastatic renal cell carcinoma
por: Deluce, Jasna, et al.
Publicado: (2022)

Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service
por: Abu-Shawer, Osama, et al.
Publicado: (2020)

Case Report: A Squamous Cell Lung Carcinoma Patient Who Responded to Neoadjuvant Immunochemotherapy but Died From Anastomosis Leakage or/and irAEs: Immune Microenvironment and Genomic Features Changes
por: Hao, Liping, et al.
Publicado: (2021)

The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer
por: Aghamajidi, Azin, et al.
Publicado: (2022)

Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 2021, 13, 6109
por: Zhang, Dongyu, et al.
Publicado: (2022)

Ira
por: Petsko, Gregory A
Publicado: (2003)

The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2021)

Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
por: Krishnamoorthy, Mithunah, et al.
Publicado: (2021)

Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy
por: Hong, Megan M Y, et al.
Publicado: (2022)

Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges
por: Krishnamoorthy, Mithunah, et al.
Publicado: (2021)

Emerging Biomarker-Guided Therapies in Prostate Cancer
por: Deluce, Jasna E., et al.
Publicado: (2022)

Dies irae : novelas breves
por: Andreyev, Leonid, 1871-1919
Publicado: (1932)

Ira : suave lluvia para heraldos negros
por: Malpica, Javier, 1965-
Publicado: (2012)

Viñas de ira /
por: Steinbeck, John, 1902-1968
Publicado: (1963)

Irás y no volverás /
por: Pacheco, José Emilio
Publicado: (1973)

Cannot write session to /tmp/vufind_sessions/sess_c4luusnbepo0si860h44hlm901